<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607304</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-CD-044</org_study_id>
    <nct_id>NCT04607304</nct_id>
  </id_info>
  <brief_title>ABCA2 GIRMS Analytical Validation Clinical Performance Study</brief_title>
  <official_title>ABCA2 GIRMS Analytical Validation Clinical Performance Study - Patient Sample Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairn Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairn Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect human breath samples for use in a validation study&#xD;
      intended to demonstrate equivalent clinical performance measures of new ABCA2 GIRMS&#xD;
      (Automated Breath Carbon Analyzer-2 Gas Isotope Ratio Mass Spectrometer) instruments to the&#xD;
      currently FDA-approved ABCA GIRMS (Automated Breath Carbon Analyzer Gas Isotope Ratio Mass&#xD;
      Spectrometer) system. ABCA GIRMS systems are used to analyze the ratio of 13CO2 to 12CO2 in&#xD;
      patient breath samples during the GEBT (Gastric Emptying Breath Test) procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the participants will be administered the FDA-approved GEBT test, which&#xD;
      involves collecting breath samples prior to and after consumption of a non-radioactive carbon&#xD;
      stable isotope (13C) labeled test meal. Breath samples will be collected at times consistent&#xD;
      with FDA approved labeling. Participant's breath samples will be analyzed on the currently&#xD;
      approved ABCA GIRMS and on the new ABCA2 GIRMS instruments. The values collected from both&#xD;
      systems will be used to determine the clinical diagnostic agreement at each individual time&#xD;
      points and percent agreement in diagnosis between the approved ABCA GIRMS and the new ABCA2&#xD;
      GIRMS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Actual">July 27, 2021</completion_date>
  <primary_completion_date type="Actual">July 27, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic agreement at each individual timepoints</measure>
    <time_frame>Up to 7 days per participant</time_frame>
    <description>Gastric emptying rates (kPCD) values compared between the validated ABCA GIRMS system and the new ABCA2 GIRMS systems for each GEBT post meal collection timepoint (45, 90, 120, 150, 180 and 240-minute timepoints) and the overall diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent agreement in diagnosis</measure>
    <time_frame>Up to 7 days per participant</time_frame>
    <description>Diagnosis compared between the comparative method (ABCA GIRMS) and the candidate method (ABCA2 GIRMS) at each post meal timepoint and the overall diagnosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>ABCA2 GIRMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leftover breath samples analyzed on ABCA2 GIRMS systems, order of analysis randomized</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABCA2 GIRMS</intervention_name>
    <description>Two systems (ABCA-C and ABCA-D) with run order randomized</description>
    <arm_group_label>ABCA2 GIRMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, 18-85 old at time of signing the informed consent form fro healthy&#xD;
             and intended use population participants (i.e. symptomology of gastroparesis). Women&#xD;
             of childbearing potential must not be pregnant at the time of GEBT administration.&#xD;
&#xD;
          -  Ability to eat test meal and provide breath samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or physical exam suggestive of pathophysiologic disorders such as renal&#xD;
             failure, chronic heart disease, chronic respiratory disease, liver disease or&#xD;
             malabsorption syndrome&#xD;
&#xD;
          -  History of abdominal surgery except appendectomy&#xD;
&#xD;
          -  Use of any medications that may alter gastric motility within two days of the study&#xD;
&#xD;
          -  Use of narcotics or anticholinergics within two days of the study&#xD;
&#xD;
          -  Females on hormone replacement therapy other than birth control medications&#xD;
&#xD;
          -  Receipt of an investigational drug within 4 weeks of the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Intolerance or allergy to any component of Gastric Emptying Breath Test meal&#xD;
&#xD;
          -  History of neurologic or psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Ryder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairn Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairn Diagnostics</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 18, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroenterology</keyword>
  <keyword>Gastric Emptying Breath Test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04607304/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

